“Now Is The Time” For Japan, Amgen Says; Inks Strategic Alliance With Astellas
This article was originally published in The Pink Sheet Daily
After selling off its Japanese subsidiary in 2008, Amgen returns via an alliance and joint venture with Astellas, with the goal of establishing a wholly owned affiliate by 2020. But challenges remain in a country known for long memories.
You may also be interested in...
The big biotech reported a strong financial quarter while updating on several R&D and business catalysts, including the potential indications for its PCSK9 inhibitor.
Eyeing the looming 2011 patent expiration of its top-seller Actos (pioglitazone), Takeda has acquired exclusive Japanese development and commercialization rights, and in one case global rights, to 13 of Amgen's clinical candidates, at a potential cost of up to $1.2 billion
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?